title: [First experiences with intravenous port systems authorized for high pressure injection of contrast agent in multiphasic computed tomography].
abstract: OBJECTIVE
  The aim of this prospective study was to examine two port systems for intravenous chemotherapy, authorized for high pressure injection, with respect to implantation, complications, implementation, and patency.
  
  
  METHODS
  40 high pressure port systems of the two available models (20 x Power Port [Bard], 20 x T-Port-Contrast [PFM]) and 20 standard port systems (X-Port [BARD]) as the control group were implanted. Both high pressure systems are authorized for injection with a maximum pressure of 300 PSI. The patient population was comprised of patients with different malignomas and liver metastases. At regular intervals following the protocol of the chemotherapy, multiphasic CT for tumor staging was carried out.
  
  
  RESULTS
  The intravenous port systems were implanted without complications under sonographic guidance with transjugular access. The mean implantation time was 30 min (range: 22 - 40 min). After a median follow-up time of 6 months, the port patency was 100%. No port infections and no complications during high pressure injection of contrast agent occurred during this period. The level of contrast measured in the aorta was equivalent to the level of contrast in the vessels when contrast agent is administered over a large peripheral intravenous access.
  
  
  CONCLUSIONS
  The intravenous high pressure port systems are equivalent to standard systems with regard to implantation and implementation. Intravenous chemotherapy can be performed as usual. The advantage is the possibility of multiphasic CT with authorized flow rates of up to 5 ml/sec.
authors.affiliation: Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke-Universität. gero.wieners@med.ovgu.de
authors.forename: G
authors.initials: G
authors.lastname: Wieners
authors.forename: U
authors.initials: U
authors.lastname: Redlich
authors.forename: O
authors.initials: O
authors.lastname: Dudeck
authors.forename: K
authors.initials: K
authors.lastname: Schütte
authors.forename: J
authors.initials: J
authors.lastname: Ricke
authors.forename: M
authors.initials: M
authors.lastname: Pech
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002283:Carcinoma, Bronchogenic / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D002405:Catheterization, Central Venous / Q000295:instrumentation*; D002408:Catheters, Indwelling; D003287:Contrast Media / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004067:Digestive System Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004867:Equipment Design; D005260:Female; D006801:Humans; D006874:Hydrostatic Pressure; D007089:Image Enhancement / Q000295:instrumentation*; D015918:Infusion Pumps, Implantable; D007275:Injections, Intravenous / Q000295:instrumentation*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D036542:Tomography, Spiral Computed / Q000295:instrumentation*
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media